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Abstract
Purpose
Plasminogen activator activity (PAA) in tears of pregnant women was investigated at various
gestation times to assess the availability of plasminogen activator for aiding potential cor-
neal wound healing processes during pregnancy.
Methods
PAA was measured by a spectrophotometric method. The analysis used 91 tear samples
from pregnant and non-pregnant women, supplemented with 10 additional tear PAA mea-
surements from non-pregnant women obtained in a previous study.
Results
Tear levels of PAA in pregnant women formed a bimodal distribution. Either the tear PAA
level was zero or non-zero during pregnancy. When non-zero, the tear PAA level was disso-
ciated from gestation time and not different than non-pregnant and post-pregnant levels.
The frequency of occurrence of zero level tear PAA increased with gestation: 16%, 17% and
46% had zero tear PAA in samples taken from women in the first, second and third trimester,
respectively.
Conclusions
Overall, of the tear samples taken from women during pregnancy, a total of 26% were at
zero tear PAA. The remaining tear samples had non-zero tear PAA values throughout ges-
tation equivalent to non-pregnant tear PAA values, suggesting local control of the source of
PAA in tears. Given the importance of the plasminogen activator system in tears to wound
healing in the cornea, and the high occurrence of zero tear PAA in our sample of pregnant
women, elective corneal surgery would be contraindicated. If corneal surgery is neverthe-
less necessary, the tear PAA level would be worth checking and patients with low level
should be closely observed during the postoperative period.
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Introduction
Major changes in hemostasis are associated with normal pregnancies [1,2]. Thrombosis is rare
in the first trimester of pregnancy but by the later trimesters both coagulation and fibrinolysis
are enhanced, thus presenting normal pregnancy as a hypercoagulable state. The plasminogen
activator/inhibitor system plays a key role. The specific serine protease plasminogen activators
convert inactive plasminogen to active plasmin, thus promoting extracellular proteolysis [3].
The coagulation activity, the anticoagulation activity, fibrinolytic and anti-fibrinolytic activity
are enhanced in normal pregnancy but these activities are balanced despite large changes in
blood levels of plasminogen activators and inhibitors [4,5]. This balance and change are
needed to control the delivery environment [6,7]. The systemic proteolytic activity needs to be
kept under sensitive control to avoid serious complications that may accompany a disturbance
of this system [8,9].
Two types of plasminogen activator exist, tissue-type plasminogen activator (tPA) and uro-
kinase-type plasminogen activator (uPA). The plasminogen activator cascade is controlled at
different levels, one of which is the inhibition of plasminogen activator activity (PAA) by plas-
minogen activator inhibitors (PAIs). The first of the two types of PAIs is the plasminogen acti-
vator inhibitor type-1 (PAI-1), which is produced by vascular smooth muscle cells, platelets
and hepatocytes. The second type of PAI is the plasminogen activator inhibitor type-2 (PAI-2),
which is mainly produced by trophoblasts and this plays an important role in inhibiting uPA
during pregnancy [10].
Plasminogen activators and PAIs are found at elevated levels in the blood of pregnant
women and in gestational tissues [11–14], During pregnancy, activity and antigen levels of
uPA are found elevated in plasma [7,15,16], peaking around the third trimester, fall during
labor, and return to normal non-pregnant levels post-partum [6].
In normal healthy eyes, uPA is a normal component of tear fluid that originates from con-
junctival and corneal epithelial cells, while tPA is not detectable in tears [17]. PAI-2 is detect-
able in tears and may play a role in the inhibition of uPA [18], but levels of PAI-1 [19] are
below the detection limit of 4 ng/ml of the ELISA test in normal non-pregnant patient’s tears.
In previous measurements on human tears, a characteristic pattern of PAA was observed
before and after corrective laser surgeries, laser in situ keratomileusis (LASIK) and photore-
fractive keratectomy (PRK) [19]. The results showed an absence of PAI-1 but a measurable
PAI-2 level present in tears prior to and after surgery [19]. An enzymatic control response to
corneal surgical wounding was asserted. In contrast, low PAA sustained over a period of three
days, evidenced in tear fluid, was an accompanying sign of corneal haze 3–6 months after the
surgery in a human study [17].
In a rabbit study, uPA was inhibited in eight eyes with aprotinin, a serine protease inhibitor,
and thereby induced haze [20]. Similar results were reported when a human patient was
treated with aprotinin after PRK [21,22]. From these results, low PAA was hypothesized to be
a possible cause of defective corneal wound healing. In another rabbit study, pregnancy was
identified as a risk factor for the development of corneal haze after photorefractive laser treat-
ment [23].
This raised a question about the level of PAI’s and PAA during pregnancy. Therefore fur-
ther previous work measured levels of PAI-2 in the tears of pregnant women at different stages
of pregnancy, finding that PAI-2 levels in tears of pregnant women were not different than the
levels found in non-pregnant women and were not correlated with gestational age [24]. In the
present work, we explore the levels of PAA in tears of pregnant women to assess the potential
risk pregnant women may have for abnormal corneal wound healing.
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Materials and methods
Subjects
Tear samples were selected for this study after obtaining written informed consent from the
women in adherence to the guidelines of the Declaration of Helsinki. Ethical approval for
this work was obtained from the University of Debrecen Ethics Committee (2155–2004). The
women were tested opportunistically either prior to pregnancy, between 9 and 39 weeks of
pregnancy, or within 1 week after delivery. Only two subjects returned for a second measure-
ment at a later gestational time: these were considered independent measurements. The sub-
jects were all healthy women with normal pregnancy, without pre- or postnatal difficulties.
None of the subjects had a history of any general disease, familial disorders, hemostatic disor-
ders, or other relevant diseases or taking of any drugs.
Before the tear sampling, the women underwent routine eye examinations, with the ante-
rior segment examined under slit lamp. All women had normal corneal surface, good visual
acuity (VA 1,0; with or without correction), no previous eye injury or surgery, no history of
any eye disease (nor in the family), no history of any general medication or topical use of eye
drops, and, during the examination of these women, no occurrence of corneal injury or inci-
sion. Contact lens wearers were excluded from the study cohort.
The number of women and their ages in each gestational category is tabulated in Table 1.
Tear sampling
Tear samples were collected from the patients’ left eyes at the outpatient clinic of the Obstetrics
and Gynecology Department, using the same, standardized collection method throughout the
study. Samples consisted of tears collected with open-ended, 70 mm long, 1.2 mm diameter
glass capillaries (VWR International LLC, Radnor, PA, USA) from the lower tear meniscus (a
horizontal thickening of the pre-corneal tear film by the lower margin) at the lateral canthus
without touching the conjunctiva. The duration of the sampling times was less than 2 minutes,
without stimulation [25] to avoid dilution from reflex tearing [26,27], Sampling times were
recorded and the secretion rates were calculated in μl/min (5–15 μl/min). Samples were centri-
fuged (1800 rpm) for 8–10 minutes right after sample collection and supernatants were deep-
frozen at -80˚C and were thawed only once for measurements.
PAA measurements
PAA was measured in the sample tears by a spectrophotometric method using human plas-
minogen and a plasmin-specific chromogenic peptide substrate, D-valyl-L-leucyl-L-lysine-p-
nitroanilide (S-2251) [28]. This assay is sensitive predominantly to urokinase plasminogen
activator [28]. Plasminogen was purchased from Abcam (Cambridge, MA, USA) and the S-
2251 was purchased from Chromogenix (Moˆlndal, Sweden). Urokinase standard was pur-
chased from Choay (Paris, France). This assay is suitable to measure plasmin activity but can
Table 1. Age (years) and number of participants in each category.
Non-Pregnant 9 to 12 Weeks 14 to 23 Weeks 25 to 39 Weeks First Postnatal Week
Mean Age 28.7 34.2 32.6 30.1 32.1
SD Age 7.9 5.7 4.5 4.9 5.4
Maximum Age 46 42 39 42 39
Minimum Age 17 19 23 21 23
Number of participants 18 19 30 24 10
https://doi.org/10.1371/journal.pone.0177003.t001
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also be used for determining plasminogen activator activity by adding plasminogen to the
reagents. Plasminogen activator activity was measured as described by Shimada and coworkers
[24] with the following modifications according to Tőzse´r and coworkers [29,30]: 5 μl tear, or
standard urokinase, or plasmin was incubated in 100 μl of 0.05 Tris buffer, pH 7.4, at 37˚C in
the presence of 0.5 mmol/l chromogenic substrate S-2251 and 1 μmol/l human plasminogen in
wells of microtiter plates. After 4 hours incubation, the reaction was terminated by the addi-
tion of 100 μl of 8 mol/l acetic acid. The absorption was measured at 405 nm with a Wallac
VICTOR2 1420 fluorimeter-luminometer (Wallac Oy, Turku, Finland). Plasminogen inde-
pendent amidolytic activity was measured similarly but plasminogen was omitted from the
incubation mixture. The absorption difference between the values obtained with and without
plasminogen was considered to be due to the plasminogen activator activity in tear, while the
absorbance value obtained without plasminogen was considered as plasminogen independent
amidolytic activity. A calibration curve was produced based on the absorption values gained in
the same system with different concentrations of urokinase standard solutions. The plasmino-
gen activator activities of the measured samples were calculated with this calibration curve and
were expressed in IU/ml urokinase equivalent values.
The tear sample measurements from women prior to pregnancy were used as a control to
compare with the tear sample measurements made on pregnant women. Due to the small
number of subjects presenting at the Obstetric Clinic before pregnancy, 10 additional PAA
measurements were added from non-pregnant women, who participated in a previous study
[17] conducted at the Department of Ophthalmology, Faculty of Medicine, University of
Debrecen. The tear collection, PAA measurement procedure, and analysis used for the previ-
ous study were the same as used in the present study. The current and previous non-pregnant
tear measurements were subsequently compared for equivalence.
Statistical methods
A total of 104 tear measurements were considered in this work and were tested against the
Grubbs criteria for outliers [31], leaving 101 measurements for further analysis, S1 Table. The
PAA values were then divided into gestational categories as follows: non-pregnant (18 sam-
ples), 9 to 12 weeks (19 samples), 14 to 23 weeks (30 samples), 25 to 39 weeks (24 samples),
and 1st postnatal week (10 samples). Tear levels of PAA were plotted against these gestational
categories. Normal distribution of samples within each gestational category was tested with
analysis of residuals from a normal plot [32]. Equivalence of PAA levels across gestational cate-
gories were tested with t-tests, median tests using a chi-squared distribution with Yates correc-
tion for continuity, Mann-Whitney U tests and one-way analysis of variance [33]. Statistical
significance was defined as p 0.05.
Results
The PAA measurements in the non-pregnant category came from two sources of measure-
ment: 10 from previously tested non-pregnant women and 8 current women tested prior to
pregnancy. Using t-tests, there was no statistically significant difference from the previous and
the current non-pregnant mean PAA values (p = 0.63) nor ages of the participants (p = 0.26).
The Mann-Whitney U tests showed no statistically significant difference from the previous
and current non-pregnant PAA median values (p> 0.99). The median test using a chi-squared
distribution with Yates correction for continuity showed no significant difference in PAA val-
ues between the two groups (p = 0.64). Accordingly, in subsequent analyses, the 18 PAA mea-
surements were considered equivalent for further analysis.
Plasminogen activator activity in tears of pregnant women
PLOS ONE | https://doi.org/10.1371/journal.pone.0177003 May 4, 2017 4 / 10
The number of tear sample measurements is shown in Fig 1 plotted against the gestational
category. In particular, the numbers of samples where the PAA value was zero are shown as
solid bars. The percentage of samples having zero PAA value compared to the total number of
samples at a particular gestation category is also shown. The percentage of zero PAA increases
with increasing gestational category;16%, 17% and 46% of the samples had zero PAA in the
first, second and third trimester, respectively, but none of the non-pregnant or post-pregnant
PAA samples had zero PAA values. In addition, in a previous study [17] on non-pregnant
healthy individuals, using the same tear collection method as used here, PAA measurements
were non-zero, including some that showed low but detectable PAA.
Because of the bimodal distribution of PAA values, the results were separated into two
groups: non-zero PAA and zero PAA for three of the gestational categories. The number of
samples and PAA results in each of the categories is given in Table 2.
The age distribution of the women in the various categories was tested with Mann-Whitney
U tests, which indicated that there were no statistically significant differences in the ages of the
participants between non-zero PAA and zero PAA within each of the three gestational catego-
ries: p = 0.96, 0.56 and 0.95, respectively. Median tests of the ages of participants between non-
Fig 1. Number of plasminogen activator activity measurements versus gestation. Shaded bars
represent the number of PAA measurements with non-zero values and solid bars represent the number
of PAA measurements with zero value (left scale). The solid line represents the percentage of PAA
measurements with zero value (right scale).
https://doi.org/10.1371/journal.pone.0177003.g001
Table 2. PAA (IU/ml) and number of participants in each category.
Non-Pregnant 9 to 12 Weeks 14 to 23 Weeks 25 to 39 Weeks First Postnatal Week
Mean Non-Zero PAA 0.325 0.243 0.309 0.348 0.339
SD Non-Zero PAA 0.184 0.129 0.180 0.228 0.217
Maximum Non-Zero PAA 0.785 0.504 0.780 0.809 0.831
Minimum Non-Zero PAA 0.050 0.005 0.076 0.046 0.191
Number (non-Zero PAA) 18 16 25 13 10
Number (zero PAA) 0 3 5 11 0
https://doi.org/10.1371/journal.pone.0177003.t002
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zero PAA and zero PAA within each of the three gestational categories showed no statistically
significant differences: p = 0.61, 0.87 and 0.71, respectively. Across all five of the gestation cate-
gories (combining non-zero PAA and zero PAA), variance of ages within a gestation period
was 31.8 while variance of ages between gestational categories was 72.0, giving a variance ratio
of 0.44 with p = 0.95. Therefore, most variance in age is between gestational categories, not in
the ages of women within the gestational categories. Tests for normal distribution of ages for
the five gestational categories showed a linear fit of the normal plot residuals: each of the five
R2 > 0.85.
The PAA results are shown in Fig 2 against gestation category. The tests for normal distri-
bution of the non-zero PAA measurements within each gestation category showed reasonable
normal distribution: each R2 > 0.61, corresponding to a linear fit of the normal plot residuals.
Using t-tests, there is no statistically significant difference between the mean PAA value at
each of the five gestation periods shown in Fig 2, p> 0.13. The median test confirmed equal
medians across the gestational age categories, p = 0.79. The Mann-Whitney U tests showed no
statistically significant difference between the median of the PAA values at each of the five ges-
tation periods compared with one another, p> 0.18. Further, the analysis of variance shows
PAA variance = 0.034 within the five gestation times and PAA variance = 0.020 between the
five gestation periods, giving a variance ratio of 1.69 with p = 0.29. Thus, most variance is
within the participants’ PAA measurements taken in the same gestation period, not between
PAA measurements taken at different gestation times.
The mean non-zero PAA levels remained essentially unchanged across categories from
non-pregnant, through pregnancy and post-pregnant. However, the number of zero PAA val-
ues increased with gestation age category, but before and after pregnancy, no zero PAA level
measurements were seen.
Fig 2. Plasminogen activator activity versus gestation. Circles represent PAA measurements with non-
zero values and triangles represent PAA measurements with zero value. Vertical error bars represent
standard deviations of PAA about the mean values. Horizontal bars represent standard deviations about the
mean position of weeks. Dotted line represents the trend of the non-zero PAA values (Y = 0.0012 X + 0.29
and R2 = 0.25).
https://doi.org/10.1371/journal.pone.0177003.g002
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One of the two women from whom tear samples were collected at two gestation categories
had a non-zero PAA value (0.427 IU/ml) before pregnancy and a zero value when measured at
9 weeks. The other woman had non-zero PAA values in both samples.
Discussion
Of the 73 measurements of PAA in tears of women who were pregnant (9 to 39 weeks) at the
time of measurement, 26% had zero levels of PAA with the fraction of women with zero PAA
increasing with later gestational age. The remaining 74% of PAA measurements in tears of
pregnant women were non-zero and those PAA levels were equivalent to the levels measured
from non-pregnant, pre-pregnant and post pregnant women.
Plasminogen activators, measured in blood samples taken from pregnant women, show a
definite dependence on the progression of pregnancy, increasing with gestation and returning
to normal levels post-partum [6,11,14–16]. In contrast, the non-zero PAA values reported here
from tears are independent of the progression of pregnancy and not influenced by changes in
systemic variations. This suggests the possibility of local control of the source of uPA in tears.
A similar conclusion was drawn with respect to PAI-2 from tears [24], where the tear-derived
PAI-2 levels were found to be independent of gestation, while PAI-2 from blood samples had a
dependence on gestation time.
Both plasminogen activators, uPA and tPA, and plasminogen activator inhibitors, PAI-1
and PAI-2, are found in gingival crevicular fluid (GCF) from both male and female subjects at
levels all more than ten times higher than in term pregnancy plasma [34]. In GCF, the concen-
tration of tPA is 10–15 times higher than uPA, while the concentration of PAI-2 is at least 5
times higher than PAI-1 [34]. Because of these ratios, the focus of attention is on tPA and PAI-
2 in GCF fluid [35,36]. Often but not always during pregnancy, a more vigorous gingival
inflammatory response to bacterial plaque is seen [37]. However, concentrations of the domi-
nant species, t-PA and PAI-2, in GCF are not significantly different between levels measured
in GCF during pregnancy and post-partum [38]. The observation is that the plasminogen
active substances in GCF are not affected by pregnancy. The implication is that they are locally
produced in the gingiva, not controlled by their concentration levels in blood [38,39].
Various biological processes including cell adhesion, cell migration, and tissue remodeling
depend on the presence of uPA. For instance, an up-regulation of uPA in corneal epithelial
cells occurs after mechanical wounding of the cornea, contributing to epithelial cell migration
[40]. For another example, allergic conjunctivitis is accompanied by elevated uPA levels in
tears and conjunctival epithelial cells, where the uPA is involved with proteolysis and cell
adhesion, cell migration and tissue remodeling [41]. These results illustrate the interlinkage
between fibrinolytic machinery and inflammatory activity [42]. What would occur if corneal
wounding or conjunctivitis happened to a pregnant woman whose uPA level is zero during
pregnancy?
Previous work found that an absence of PAA in tears after laser vision correction surgery
correlated with a tendency to incur an incomplete corneal wound healing experience [17,20,
23] and that pregnancy was a risk factor for developing corneal haze after PRK [23]. Pregnancy
can be accompanied by changes in refraction and other corneal properties [43,44]. Eyes of
women who became pregnant after PRK have experienced refractive regression and corneal
haze [45]. Changes in visual acuity and spherical equivalent have been reported in eyes of
women who became pregnant after LASIK [46]. Although pregnancy normally precludes cor-
neal laser surgery [47], sometimes an early stage pregnancy has inadvertently not been identi-
fied. Also, traumatic corneal injury may require corneal surgery or other procedures involving
wound healing.
Plasminogen activator activity in tears of pregnant women
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With the increase in prevalence of myopia worldwide [48–51], especially among younger
people, LASIK and PRK are procedures often chosen for amelioration. Thus corneal wound
healing becomes increasingly important, including a need to be sensitive to changes in tear
enzymes that affect the corneal wound healing process. The level or absence of enzymes in
tears during pregnancy should be an important consideration when corneal surgery on a preg-
nant woman is contemplated.
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